Novartis labeling changes
This article was originally published in The Tan Sheet
Labeling of firm's Transderm Scop Rx motion sickness patch modified to remove statement claiming superiority over Pharmacia's OTC remedy Dramamine (oral dimenhydrinate), according to FDA's May 10 letter responding to Pharmacia petition. Agency determined comparative statement "is not supported by any data in Novartis' [NDA] for Transderm Scop," and requested it be removed from labeling. Novartis complied in a labeling supplement approved March 22. Novartis also removed superiority claim from DTC print ads, Web site after National Advertising Division determined evidence was insufficient to support the statement (1"The Tan Sheet" Nov. 13, 2000, p. 11)...
You may also be interested in...
DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.
With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.